Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis-Reference-Cited by-同舟云学术

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

Published:2008-02-15 Issue:4 Volume:111 Page:1862-1865
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Vener Claudia¹,Fracchiolla Nicola Stefano¹,Gianelli Umberto²,Calori Rossella¹,Radaelli Franca³,Iurlo Alessandra³,Caberlon Sabrina⁴,Gerli Giancarla⁴,Boiocchi Leonardo²,Deliliers Giorgio Lambertenghi¹

Affiliation:

1. Ematologia I, Centro Trapianti di Midollo, University of Milan, Fondazione Istituto di ricovero e cura a carattere scientifico (IRCCS) Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan;

2. II Cattedra di Anatomia Patologica, Dipartimento di Medicina, Chirurgia, E Odontoiatria (DMCO), A. O. San Paolo, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan;

3. Divisione di Ematologia, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan; and

4. Unità di Ematologia e Trombosi, Ospedale San Paolo, DMCO, University of Milan, Milan, Italy

Abstract

Various clinical prognostic scoring systems (PSSs) have been suggested as means of selecting high-risk chronic idiopathic myelofibrosis (CIMF) patients at diagnosis. The WHO has recently proposed strict diagnostic criteria for CIMF, and the European consensus for bone marrow fibrosis (BMF) grading recommends 4 classes. It has been suggested that BMF grading may play a prognostic role in CIMF, but it has never been compared with the other PSSs in the same patients. We tested a prognostic model for overall survival (OS) based on the WHO criteria and BMF grading in 113 consecutive patients with chronic myeloproliferative disorders (98 with CIMF and 15 with postpolycythemic myelofibrosis), and compared the findings with those of PSSs. The results showed that our model is significantly associated with different OSs and, unlike the other PSSs, clearly discriminates the OS of intermediate- and high-risk patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/111/4/1862/1221339/zh800408001862.pdf

Reference18 articles.

1. Myelofibrosis with myeloid metaplasia.;Tefferi;N Engl J Med,2000

2. New insights into the pathogenesis and drug treatment of myelofibrosis.;Tefferi;Curr Opin Hematol,2006

3. New approaches in the treatment of myelofibrosis.;Hennessy;Cancer,2005

4. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.;Barosi;J Clin Oncol,1999

5. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.;Reeder;Blood,2003

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia;Cancers;2023-08-20

2. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database;Cancers;2023-08-15

3. Three‐dimensional spatial mapping of the human hematopoietic microenvironment in healthy and diseased bone marrow;Cytometry Part A;2023-07-21

4. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis;HemaSphere;2022-12-20

5. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients;Leukemia;2022-12-05